Fertilis Pty, Ltd. appears in FDA records as the applicant for a single assisted-reproduction submission. The 510(k) database entry lists the Fertilis microICSI Device under product code MQK, regulation 884.6160, device class 2, with the review panel recorded as Obstetrics/Gynecology. The filing was received on 22 June 2026 and decided on 9 October 2026 with decision code SESE, meaning Substantially Equivalent. The clearance type is Traditional, the third-party flag is N, and the record notes that a summary is available. The applicant address in the filing is S310 / 1 Frome Rd., Helen Mayo S. Bldg., The University Of Adelaide, Adelaide, with postal code 5005 and country code AU; that is a filing address, not a verified headquarters. [1][4][5]
The documented product and its regulatory scope
The only product tied to this applicant in the supplied filings is the Fertilis microICSI Device, cleared as substantially equivalent under K262090. FDA classifies it as Labware, Assisted Reproduction, within the Obstetrics/Gynecology medical specialty, and the submission is a Traditional 510(k) reviewed by the OB panel rather than a third-party review. The record indicates a summary statement accompanies the clearance. Beyond the device name, product code, regulation number and classification, the filing data does not describe components, materials or intended-use wording. [1][4][5]
Company background as published by Fertilis
Fertilis states on its own site that it was founded in 2019 in Adelaide, Australia, and that the underlying idea originated in the late 1990s with Co-Founder and Chief Scientific Officer Prof. Jeremy. The company frames its purpose around precision tools intended to protect embryos and support embryologists. Its published team listing names Peter Rowland as Chairman and Non-Executive Director, Kim Giliam and Robert Noble as Non-Executive Directors, and John Santich as Company Secretary, described as a co-founder with engineering and law qualifications. These are company-published statements, not independently verified facts. [2]
Published research and conference material
A peer-reviewed paper in the Journal of Assisted Reproduction and Genetics, published 18 January 2024, carries the title describing a micro-fabricated device (microICSI) and reports work on porcine blastocyst development and procedural efficiency for porcine intracytoplasmic sperm injection and human microinjection. Fertilis lists on its news page an abstract dated 9 August 2026 for FSANZ 2026 concerning a suction-free microICSI device and operator dependence in Piezo-ICSI. The supplied excerpts give titles and dates only; they do not provide outcome figures, and none should be inferred from the titles. [3][6]
What the record does and does not establish
The supplied collection contains one linked record, a 510(k) with a SESE decision, and the sample of one record carries the same decision. That count reflects the filings retrieved as of the snapshot date and is not a measure of total portfolio, sales or safety performance. No recalls appear in the recall sample. The sources do not identify a parent company, brand owner, website domain, customers, certifications or commercial availability, and no ownership relationship is verified. Whether additional submissions exist outside the retrieved data is unknown. [1][4]

